Exemestane

Manufactured by Pfizer

Sourced in United States

Exemestane is a laboratory product manufactured by Pfizer for research and scientific purposes. It is a steroidal aromatase inhibitor used in the study of hormone-dependent processes.

Automatically generated - may contain errors

Lab products found in correlation

P70 s6 kinase, by Cell Signaling Technology (1 mentions) Cobalt chloride cocl2, by Merck Group (1 mentions) β actin, by Cell Signaling Technology (1 mentions) Actinomycin d, by Merck Group (1 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Trastuzumab, by Genentech (1 mentions) Hif 1α, by BD (1 mentions) Letrozole, by Novartis (1 mentions)

3 protocols using exemestane

Breast Cancer Drug Combination Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following drugs were used: letrozole (Novartis, NY, USA); lapatinib (GlaxoSmithKline Pharmaceutical, Brentford, Middlesex, United Kingdom); trastuzumab (Genentech, San Francisco, CA); exemestane (Pfizer, NY, USA); cycloheximide (#C1988), actinomycin D (#A9415), and cobalt chloride (CoCl₂; #C8661) (all from Sigma, St. Louis, MO). The following antibodies were used in western blot analyses: HER2 (#04-1127) and BCRP (EMD Millipore, Billerica, MA); HIF-1α (#610959; BD Biosciences); ERα (#8644; Cell Signaling Technology, Danvers, MA); phosphorylated and total ERK1/2, Akt (#4058 and #4685), mTOR (#2971 and #2972) and p70 S6 kinase (#9205 and #9202) all from Cell signaling Technology, Danvers, MA); and β-actin (#4970; Cell Signaling Technology, Danvers, MA).

Kazi A.A., Gilani R.A., Schech A.J., Chumsri S., Sabnis G., Shah P., Goloubeva O., Kronsberg S, & Brodie A.H. (2014). Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Research : BCR, 16(1), R15.

+ Open protocol

+ Expand

Exemestane Plus Goserelin for Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Treatment was initiated within 4 weeks of enrollment. Each patient received a 25-mg tablet of exemestane (Pfizer, New York) by mouth once daily. A subcutaneous injection of 3.6 mg goserelin (Zoladex, AstraZeneca, London, UK) was administered in the lower abdomen every 4 weeks. The patients were followed up, and outcomes were confirmed in June 2014. Treatment was terminated if progressive disease (PD) developed or unacceptable adverse events occurred. Progression-free survival (PFS) was considered the primary end point for our study. Objective response rate (ORR), duration of response (DOR), and clinical benefit rate (CBR) based on complete response (CR), partial response (PR), or stable disease (SD) for ≥6 months were considered secondary endpoints.

Wang J., Xu B., Yuan P., Ma F., Li Q., Zhang P., Cai R., Fan Y., Luo Y, & Li Q. (2015). Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. Medicine, 94(26), e1006.

+ Open protocol

+ Expand

Postmenopausal High-Risk Breast Cancer Prevention

Check if the same lab product or an alternative is used in the 5 most similar protocols

Postmenopausal women at increased risk for breast cancer were enrolled at two clinical research hospitals in the eastern United States. Women were defined as postmenopausal if they had no menses for at least 12 months or bilateral oopherectomy. In unclear cases, (e.g. 50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with FSH>35 U/L. The trial protocol was approved by IRBs at both participating sites (NCI 04-C-0044, GT 07-313). Women were considered high risk by any one of the following criteria: Gail Model (26 (link)) risk ≥1.7 over 5 years; history of lobular neoplasia or atypical ductal hyperplasia; DCIS treated with mastectomy or lumpectomy and radiation; stage I/II breast cancer at least two years from completing treatment for invasive disease; or BRCA1/2 mutation carrier. Additionally, women were required to have no osteoporosis on BMD scan (AP spine T score > −2.5) and no prior AI therapy, but prior use of menopausal hormone therapy (MHT) and SERMs was allowed. Women were required to have stopped MHT, tamoxifen, or raloxifene for at least three months before enrollment. Women were given 25mg of exemestane (Pfizer, Inc.) daily for two years with calcium carbonate 1200 mg and Vitamin D 400 international units daily.

Gatti-Mays M., Venzon D., Galbo C., Singer A., Reynolds J., Makariou E., Kallakury B., Heckman-Stoddard B., Korde L., Isaacs C., Warren R., Gallagher A, & Eng-Wong J. (2016). Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety. Cancer prevention research (Philadelphia, Pa.), 9(3), 225-233.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!